Управленческое творчество. Методология познания и творчества. Алексей Марковский
Jewish Vanguard Circle
27.12.2023 @WinkRus
The Worst President Ever
COMMENTS
Mark Yarmarkovich, PhD
The Yarmarkovich lab aims to enable the development of personalized immunotherapies (CAR T cells, TCRs and BiTEs) for all cancer patients. Our work spans the entire workflow from target discovery to clinical application. We work at the multidisciplinary intersection of genomics, proteomics, immunology, protein engineering and computational ...
Team
[email protected]. Dr. Mark Yarmarkovich is focused on developing safe and effective cancer immunotherapies through innovations in biotechnology. He has worked in industry at Genentech and completed his PhD at the University of Pennsylvania and postdoctoral work with John Maris at the Children's Hospital of Philadelphia.
Yarmarkovich Lab
Our team operates at the dynamic crossroads of genomics, proteomics, immunology, antibody engineering, and computational biology, developing and implementing cutting-edge technologies to safely and effectively treat cancer. We are generating a pipeline of new therapies for cancer patients in need and developing technologies to enable ...
Mark Yarmarkovich
Mark Yarmarkovich. NYU Grossman School of Medicine. Verified email at nyulangone.org - Homepage. ... M Yarmarkovich, QF Marshall, JM Warrington, R Premaratne, A Farrel, ... Nature 623 (7988), 820-827, 2023. 11: 2023: When cold is hot: immune checkpoint inhibition therapy for rhabdoid tumors.
Team Original
Dr. Mark Yarmarkovich is focused on developing safe and effective cancer immunotherapies through innovations in biotechnology. He has worked in industry at Genentech and completed his PhD at the University of Pennsylvania and postdoctoral work with John Maris at the Children's Hospital of Philadelphia, working across a number of disciplines including oncology, protein chemistry, immunology ...
STAT Wunderkind "Blazing New Trails:" Q&A With Mark Yarmarkovich, PhD
shafere1 [at] chop.edu (By Emily Shafer). Editor's note: A hearty congratulations to Mark Yarmarkovich, PhD, for being named a 2021 STAT Wunderkind! Each year, STAT, a news site that reports on health, medicine, and the life sciences, names its STAT Wunderkinds, the next generation of scientific superstars, who are selected from hundreds of nominations across North America.
Mark YARMARKOVICH
Mark Yarmarkovich John M. Maris Carcinogen-induced cancers typically have high mutation burdens and an inflamed microenvironment and thus are poised to respond to immune checkpoint inhibitors (ICIs).
Mark Yarmarkovich
Mark Yarmarkovich saw a revolution unfolding in cancer care, and he wanted in. It was around 2012 when the scientist saw early data on CAR-T, a newfangled therapy in which a patient's own immune ...
Dr Mark Yarmarkovich
Mark. Last Name. Yarmarkovich. Organisation. New York University. Biography. My work converges at a longstanding interest is in developing safer and more effective therapies for cancer and a fascination with the function of the immune system. Following these interests over the past two decades, I have had the privilege of working with world ...
Engineering CAR-T Cells to Target Intracellular Cancer Drivers
Mark Yarmarkovich, PhD Assistant Professor, Dept. of Pathology Perlmutter Cancer Center, NYU Grossman School of Medicine. Abstract: Dr. Yarmarkovich's research is centered around the development of personalized immuno- therapies (CAR T cells, TCRs and BiTEs) for all cancer patients. His groups work spans the entire workflow from target ...
CHOP Researchers Develop a New Class of CAR-T Cells that Target
"This research is extremely exciting because it raises the possibility of targeting very specific tumor molecules, expanding both the cancers that can be treated with immunotherapy and the patient population who can benefit," said Mark Yarmarkovich, PhD, an investigator in the Maris Laboratory at Children's Hospital of Philadelphia and ...
Targeting intracellular cancer drivers using CAR T cells; Mark
Targeting intracellular cancer drivers using CAR T cells; Mark Yarmarkovich, PhD. Mar 31, 2022 (Thu) | 1:00 PM -2:00 PM ... Stanford, CA. Mark Yarmarkovich, a lab investigator candidate, will be virtually presenting his talk titled, Targeting intracellular cancer drivers using CAR T cells" on Thursday, March 31, 2022 from 1pm-2pm.
ORCID
Mark Yarmarkovich expand_more. Education and qualifications (1) sort Sort. University of Pennsylvania: Philadelphia, Pennsylvania, US . 2012-09-01 to 2019-05-19 | PhD (Oncology) Education Show more detail. Source: Mark Yarmarkovich How many people are using ORCID? The text of this website is published under a CC0 ...
New Kind of CAR T-Cell Changes Scientists' Approach to Solid Tumors
In Nature, its developers, John Maris, MD, a lifelong neuroblastoma physician-scientist, and Mark Yarmarkovich, PhD, investigator in the Maris Lab, successfully showed that PC-CARS not only targeted previously unreachable proteins inside cancer cells, but also led to the complete elimination of neuroblastoma tumors in an animal model.
Maris Laboratory News & Announcements
Dr. Mark Yarmarkovich, PhD, a senior scientist at CHOP, is a 2021 STAT Wunderkind. CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers. Published on Nov 3, 2021 in Press Releases .
Publications
Yang J, Hotz T, Broadnax L, Yarmarkovich M, Elbaz-Younes I, Hirschi KD. Anomalous uptake and circulatory characteristics of the plant-based small RNA MIR2911. (2016) Scientific Reports. Yarmarkovich M, Hirschi KD. Digesting dietary miRNA therapeutics. (2015) Oncotarget. Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW.
Molecular Oncology & Tumor Immunology PhD Training Program Mentoring
Mark Yarmarkovich, PhD Assistant Professor, Department of Pathology Research interests: expanding immunotherapies through tumor antigen discovery, CAR T engineering, cross-HLA targeting, and development of molecular technologies; use of proteomics, genomics, protein engineering, immunology, and computational biology ...
New Class of "Peptide-Centric" CAR-T Cells Eradicates Tumors in Mice
Yarmarkovich is first author, and Maris senior author, of the team's published paper in Nature, which is titled, "Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs ...
CHOP Researchers Develop a New Class of CAR-T Cells that Target
Yarmarkovich et al. "Therapeutic Targeting of Intracellular Oncoproteins with Peptide-Centric CAR T Cells," Nature, November 3, 2021, DOI: 10.1038/s41586-021-04061-6 About Children's Hospital of ...
Mark Yarmarkovich
Abstract 4384: Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance. by Mark Yarmarkovich. BACKGROUND: Neuroblastoma (NBL) is the most common extracranial solid tumor in children. High-risk NBLs progress to metastatic disease and have 5-year survival of only ∼40% ...
JPMorgan's Kolanovic to Exit Amid String of Poor Stock Calls
Marko Kolanovic, JPMorgan Chase & Co.'s chief global market strategist and co-head of global research, is leaving the bank, according to an internal memo obtained by Bloomberg News.
IMAGES
VIDEO
COMMENTS
The Yarmarkovich lab aims to enable the development of personalized immunotherapies (CAR T cells, TCRs and BiTEs) for all cancer patients. Our work spans the entire workflow from target discovery to clinical application. We work at the multidisciplinary intersection of genomics, proteomics, immunology, protein engineering and computational ...
[email protected]. Dr. Mark Yarmarkovich is focused on developing safe and effective cancer immunotherapies through innovations in biotechnology. He has worked in industry at Genentech and completed his PhD at the University of Pennsylvania and postdoctoral work with John Maris at the Children's Hospital of Philadelphia.
Our team operates at the dynamic crossroads of genomics, proteomics, immunology, antibody engineering, and computational biology, developing and implementing cutting-edge technologies to safely and effectively treat cancer. We are generating a pipeline of new therapies for cancer patients in need and developing technologies to enable ...
Mark Yarmarkovich. NYU Grossman School of Medicine. Verified email at nyulangone.org - Homepage. ... M Yarmarkovich, QF Marshall, JM Warrington, R Premaratne, A Farrel, ... Nature 623 (7988), 820-827, 2023. 11: 2023: When cold is hot: immune checkpoint inhibition therapy for rhabdoid tumors.
Dr. Mark Yarmarkovich is focused on developing safe and effective cancer immunotherapies through innovations in biotechnology. He has worked in industry at Genentech and completed his PhD at the University of Pennsylvania and postdoctoral work with John Maris at the Children's Hospital of Philadelphia, working across a number of disciplines including oncology, protein chemistry, immunology ...
shafere1 [at] chop.edu (By Emily Shafer). Editor's note: A hearty congratulations to Mark Yarmarkovich, PhD, for being named a 2021 STAT Wunderkind! Each year, STAT, a news site that reports on health, medicine, and the life sciences, names its STAT Wunderkinds, the next generation of scientific superstars, who are selected from hundreds of nominations across North America.
Mark Yarmarkovich John M. Maris Carcinogen-induced cancers typically have high mutation burdens and an inflamed microenvironment and thus are poised to respond to immune checkpoint inhibitors (ICIs).
Mark Yarmarkovich saw a revolution unfolding in cancer care, and he wanted in. It was around 2012 when the scientist saw early data on CAR-T, a newfangled therapy in which a patient's own immune ...
Mark. Last Name. Yarmarkovich. Organisation. New York University. Biography. My work converges at a longstanding interest is in developing safer and more effective therapies for cancer and a fascination with the function of the immune system. Following these interests over the past two decades, I have had the privilege of working with world ...
Mark Yarmarkovich, PhD Assistant Professor, Dept. of Pathology Perlmutter Cancer Center, NYU Grossman School of Medicine. Abstract: Dr. Yarmarkovich's research is centered around the development of personalized immuno- therapies (CAR T cells, TCRs and BiTEs) for all cancer patients. His groups work spans the entire workflow from target ...
"This research is extremely exciting because it raises the possibility of targeting very specific tumor molecules, expanding both the cancers that can be treated with immunotherapy and the patient population who can benefit," said Mark Yarmarkovich, PhD, an investigator in the Maris Laboratory at Children's Hospital of Philadelphia and ...
Targeting intracellular cancer drivers using CAR T cells; Mark Yarmarkovich, PhD. Mar 31, 2022 (Thu) | 1:00 PM -2:00 PM ... Stanford, CA. Mark Yarmarkovich, a lab investigator candidate, will be virtually presenting his talk titled, Targeting intracellular cancer drivers using CAR T cells" on Thursday, March 31, 2022 from 1pm-2pm.
Mark Yarmarkovich expand_more. Education and qualifications (1) sort Sort. University of Pennsylvania: Philadelphia, Pennsylvania, US . 2012-09-01 to 2019-05-19 | PhD (Oncology) Education Show more detail. Source: Mark Yarmarkovich How many people are using ORCID? The text of this website is published under a CC0 ...
In Nature, its developers, John Maris, MD, a lifelong neuroblastoma physician-scientist, and Mark Yarmarkovich, PhD, investigator in the Maris Lab, successfully showed that PC-CARS not only targeted previously unreachable proteins inside cancer cells, but also led to the complete elimination of neuroblastoma tumors in an animal model.
Dr. Mark Yarmarkovich, PhD, a senior scientist at CHOP, is a 2021 STAT Wunderkind. CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers. Published on Nov 3, 2021 in Press Releases .
Yang J, Hotz T, Broadnax L, Yarmarkovich M, Elbaz-Younes I, Hirschi KD. Anomalous uptake and circulatory characteristics of the plant-based small RNA MIR2911. (2016) Scientific Reports. Yarmarkovich M, Hirschi KD. Digesting dietary miRNA therapeutics. (2015) Oncotarget. Zheng K, Yarmarkovich M, Bantog C, Bayer R, Patapoff TW.
Mark Yarmarkovich, PhD Assistant Professor, Department of Pathology Research interests: expanding immunotherapies through tumor antigen discovery, CAR T engineering, cross-HLA targeting, and development of molecular technologies; use of proteomics, genomics, protein engineering, immunology, and computational biology ...
Yarmarkovich is first author, and Maris senior author, of the team's published paper in Nature, which is titled, "Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs ...
Yarmarkovich et al. "Therapeutic Targeting of Intracellular Oncoproteins with Peptide-Centric CAR T Cells," Nature, November 3, 2021, DOI: 10.1038/s41586-021-04061-6 About Children's Hospital of ...
Abstract 4384: Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance. by Mark Yarmarkovich. BACKGROUND: Neuroblastoma (NBL) is the most common extracranial solid tumor in children. High-risk NBLs progress to metastatic disease and have 5-year survival of only ∼40% ...
Now hiring outstanding and creative technicians, postdocs, scientists and PhD students. You will join an international multi-disciplinary team focused on developing the next-generation of cancer immunotherapies. ... [email protected] ©2024 Yarmarkovich Lab.
Marko Kolanovic, JPMorgan Chase & Co.'s chief global market strategist and co-head of global research, is leaving the bank, according to an internal memo obtained by Bloomberg News.